Publications
Detailed Information
Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Ji Won | - |
dc.contributor.author | Lee, Kook Lae | - |
dc.contributor.author | Jeong, Ji Bong | - |
dc.contributor.author | Kim, Byeong Gwan | - |
dc.contributor.author | Kim, Joo Sung | - |
dc.contributor.author | Song, In Sung | - |
dc.contributor.author | Jung, Hyun Chae | - |
dc.contributor.author | Shin, Sue | - |
dc.date.accessioned | 2012-05-23T00:41:28Z | - |
dc.date.available | 2012-05-23T00:41:28Z | - |
dc.date.issued | 2010-07-28 | - |
dc.identifier.citation | WORLD JOURNAL OF GASTROENTEROLOGY; Vol.16 28; 3573-3577 | ko_KR |
dc.identifier.issn | 1007-9327 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76284 | - |
dc.description.abstract | Aim: To investigate the risk factors for Clostridium-difficile-associated diarrhea (CDAD) recurrence, and its relationship with proton pump inhibitors (PPIs). METHODS: Retrospective data of 125 consecutive hospitalized patients diagnosed with CDAD between January 2006 and December 2007 were collected by medical chart review. Collected data included patient characteristics at baseline, underlying medical disease, antibiotic history before receiving a diagnosis of CDAD, duration of hospital stay, severity of CDAD, concurrent treatment with PPIs, laboratory parameters, response to CDAD therapy, and recurrence of disease within 90 d of successful treatment. Various clinical and laboratory parameters were compared in patients in whom CDAD did or did not recur. RESULTS: Of the 125 patients (mean age, 67.6 +/- 13.9 years) that developed CDAD, 98 (78.4%) did not experience recurrence (non-recurrent group) and 27 (21.6%) experienced one or more recurrences (recurrent group). Prior to the development of CDAD, 96% of the 125 patients were prescribed antibiotics, and 56 (44.8%) of the patients received PPIs. Age older than 65 years (P = 0.021), feeding via nasogastric tube (NGT) (P = 0.045), low serum albumin level (P = 0.025), and concurrent use of PPIs (P = 0.014) were found to be risk factors for CDAD recurrence by univariate analysis. However, sex, length of hospital stay, duration and type of antibiotics used, severity of disease, leukocyte count and C-reactive protein (CRP) were not associated with risk of CDAD recurrence. On multivariate analysis, the important risk factors were advanced age (> 65 years, adjusted OR: 1.32, 95% CI: 1.12-3.87, P = 0.031), low serum albumin level (< 2.5 g/dL, adjusted OR: 1.85, 95% CI: 1.35-4.91, P = 0.028), and concurrent use of PPIs (adjusted OR: 3.48, 95% CI: 1.64-7.69, P = 0.016). CONCLUSION: Advanced age, serum albumin level < 2.5 g/dL, and concomitant use of PPIs were found to be significant risk factors for CDAD recurrence. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | W J G PRESS | ko_KR |
dc.subject | Clostridium difficile | ko_KR |
dc.subject | Diarrhea | ko_KR |
dc.subject | Recurrence | ko_KR |
dc.subject | Proton pump inhibitors | ko_KR |
dc.subject | Risk factors | ko_KR |
dc.title | Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 김지원 | - |
dc.contributor.AlternativeAuthor | 이국래 | - |
dc.contributor.AlternativeAuthor | 정지봉 | - |
dc.contributor.AlternativeAuthor | 김병관 | - |
dc.contributor.AlternativeAuthor | 신수 | - |
dc.contributor.AlternativeAuthor | 김주성 | - |
dc.contributor.AlternativeAuthor | 정현채 | - |
dc.contributor.AlternativeAuthor | 송인성 | - |
dc.identifier.doi | 10.3748/wjg.v16.i28.3573 | - |
dc.citation.journaltitle | WORLD JOURNAL OF GASTROENTEROLOGY | - |
dc.description.citedreference | Leffler DA, 2009, GASTROENTEROLOGY, V136, P1899, DOI 10.1053/j.gastro.2008.12.070 | - |
dc.description.citedreference | Hookman P, 2009, WORLD J GASTROENTERO, V15, P1554, DOI 10.3748/wjg.15.1554 | - |
dc.description.citedreference | Garey KW, 2008, J HOSP INFECT, V70, P298, DOI 10.1016/j.jhin.2008.08.012 | - |
dc.description.citedreference | Aseeri M, 2008, AM J GASTROENTEROL, V103, P2308, DOI 10.1111/j.1572-0241.2008.01975.x | - |
dc.description.citedreference | Chang JY, 2008, J INFECT DIS, V197, P435, DOI 10.1086/525047 | - |
dc.description.citedreference | Cadle RM, 2007, AM J HEALTH-SYST PH, V64, P2359, DOI 10.2146/ajhp060629 | - |
dc.description.citedreference | Jump RLP, 2007, ANTIMICROB AGENTS CH, V51, P2883, DOI 10.1128/AAC.01443-06 | - |
dc.description.citedreference | Akhtar AJ, 2007, J NATL MED ASSOC, V99, P500 | - |
dc.description.citedreference | Rao A, 2006, ANTIMICROB AGENTS CH, V50, P3901, DOI 10.1128/AAC.01506-05 | - |
dc.description.citedreference | Yearsley KA, 2006, ALIMENT PHARM THERAP, V24, P613, DOI 10.1111/j.1365-2036.2006.03015.x | - |
dc.description.citedreference | Maroo S, 2006, GASTROENTEROLOGY, V130, P1311, DOI 10.1053/j.gastro.2006.02.044 | - |
dc.description.citedreference | Dial S, 2005, JAMA-J AM MED ASSOC, V294, P2989 | - |
dc.description.citedreference | Aslam S, 2005, LANCET INFECT DIS, V5, P549 | - |
dc.description.citedreference | Pepin J, 2005, CLIN INFECT DIS, V40, P1591 | - |
dc.description.citedreference | Pepin J, 2004, CAN MED ASSOC J, V171, P466, DOI 10.1503/cmaj.1041104 | - |
dc.description.citedreference | Cunningham R, 2003, J HOSP INFECT, V54, P243, DOI 10.1016/S0195-6701(03)00088-4 | - |
dc.description.citedreference | Zedtwitz-Liebenstein K, 2002, CRIT CARE MED, V30, P1118 | - |
dc.description.citedreference | Kyne L, 2001, GUT, V49, P152, DOI 10.1136/gut.49.1.152 | - |
dc.description.citedreference | Mylonakis E, 2001, ARCH INTERN MED, V161, P525 | - |
dc.description.citedreference | Kyne L, 2001, LANCET, V357, P189 | - |
dc.description.citedreference | McFarland LV, 1999, INFECT CONT HOSP EP, V20, P43 | - |
dc.description.citedreference | Do AN, 1998, CLIN INFECT DIS, V26, P954 | - |
dc.description.citedreference | Lai KK, 1997, INFECT CONT HOSP EP, V18, P628 | - |
dc.description.citedreference | Fekety R, 1997, CLIN INFECT DIS, V24, P324 | - |
dc.description.citedreference | Lowenkron SE, 1996, INTENS CARE MED, V22, P990 | - |
dc.description.citedreference | IMPALLOMENI M, 1995, BRIT MED J, V311, P1345 | - |
dc.description.citedreference | PRON B, 1995, EUR J CLIN MICROBIOL, V14, P599 | - |
dc.description.citedreference | MCFARLAND LV, 1994, JAMA-J AM MED ASSOC, V271, P1913 | - |
dc.description.citedreference | VERDU E, 1994, GUT, V35, P455 | - |
dc.description.citedreference | WARNY M, 1994, INFECT IMMUN, V62, P384 | - |
dc.description.citedreference | MCFARLAND LV, 1990, J INFECT DIS, V162, P678 | - |
dc.description.citedreference | WILSON KH, 1985, J INFECT DIS, V151, P355 | - |
dc.description.tc | 13 | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.